Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that release of two pre-recorded videos aired at the completion of the Company’s Annual and Special Meeting, held at the Company’s corporate office on June 30, 2017.

 

The pre-recorded videos feature Dr. Michael Jewett, uro-oncologist of Princess Margaret Cancer Centre, University Health Network (“UHN”) and Dr. Girish Kulkarni, uro-oncologist, UHN.

 

A You Tube link to both videos can be found at:

 

Dr. Jewett

 

https://youtu.be/0awLP-R5gRA

 

Dr. Kulkarni

 

https://youtu.be/3P_Pvq1kzVc

 

Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is delighted to be associated with both Dr. Jewett and Dr. Kulkarni and their combined expertise in the field of uro-oncology. Their experience and guidance is key to assisting Theralase in the successful completion of a Phase Ib clinical study for the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”). The Phase Ib NMIBC clinical study, for the first three patients, successfully met its primary and secondary outcome measures of safety and tolerability and pharmacokinetics (movement and exit of drug within tissue), respectively, as determined by an independent Data Safety Monitoring Board (“DSMB”). The Company will report out on the exploratory endpoint of efficacy, when sufficient clinical data has been collected to intelligently report out on this outcome measure. The DSMB has authorized UHN to enroll an additional 6 patients for the second phase of the Phase Ib clinical study to be treated at a therapeutic dose of the light activated drug, TLD-1433, (0.70 mg/cm2), currently in progress.”

 

About Theralase Technologies Inc.

 

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.

 

Additional information is available at www.theralase.com and www.sedar.com .

 

This news release contains "forward-looking statements" which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as "may", "would", "could", “should”, "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

 

For More Information:

 

Roger Dumoulin-White

President & CEO

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225

rwhite@theralase.com

www.theralase.com

To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/Theralase07052017.pdf

Source: Theralase Technologies Inc. (TSX Venture:TLT, OTCQX:TLTFF)

To follow Theralase Technologies Inc. on your favorite social media platform or financial websites, please click on the icons below.

 

Maximum News Dissemination by FSCwire. http://www.fscwire.com

 

Copyright © 2017 Filing Services Canada Inc.